The study will assemble a longitudinal cohort of more than 195,000 pregnant women (>22,000 women with SARS-CoV-2 infection during pregnancy and approximately >173,000 without) between March 2020 and December 2022. We will use our comprehensive EHR to follow women and their children for up to 5 years. We will assess whether women with SARS-CoV-2 infection during pregnancy are at higher risk of developing adverse cardiometabolic outcomes or neuropsychiatric outcomes after pregnancy than women without SARS-CoV-2 infection. We will also assess whether children exposed in utero to SARS-CoV-2 infection are at higher risk for altered growth trajectories and neurodevelopmental delays than children without in utero exposure to SARS-CoV-2. We will also recruit and survey a subsample of 2000 of the mother-child dyads when the child is 3 years old to ascertain women’s and children’s self/parent-reported subclinical health outcomes not available in the EHR, but that may suggest a need to monitor and/or provide early interventions.